MYGN
Myriad Genetics, Inc. Healthcare - Diagnostics & Research Investor Relations →
Myriad Genetics, Inc. (MYGN) closed at $5.12 as of 2026-02-02, trading 69.9% below its 200-week moving average of $17.01. This places MYGN in the extreme value zone. The stock is currently moving closer to the line, down from -67.1% last week. With a 14-week RSI of 28, MYGN is in oversold territory.
Over the past 1535 weeks of data, MYGN has crossed below its 200-week moving average 28 times. On average, these episodes lasted 29 weeks. The average one-year return after crossing below was -10.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $477 million, MYGN is a small-cap stock. The company generates a free cash flow yield of 2.0%. Return on equity stands at -72.5%. The stock trades at 1.3x book value.
Share count has increased 14.1% over three years, indicating dilution.
Over the past 29.5 years, a hypothetical investment of $100 in MYGN would have grown to $90, compared to $1678 for the S&P 500. MYGN has returned -0.3% annualized vs 10.0% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: MYGN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MYGN Crosses Below the Line?
Across 28 historical episodes, buying MYGN when it crossed below its 200-week moving average produced an average return of -11.8% after 12 months (median -16.0%), compared to +14.0% for the S&P 500 over the same periods. 39% of those episodes were profitable after one year. After 24 months, the average return was -6.2% vs +32.1% for the index.
Each line shows $100 invested at the moment MYGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MYGN has crossed below its 200-week MA 28 times with an average 1-year return of +-10.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 1996 | Jan 1997 | 18 | 13.3% | -2.6% | -7.8% |
| Apr 1997 | Jun 1997 | 7 | 22.8% | +4.0% | +3.8% |
| Jun 1997 | Nov 1999 | 124 | 68.9% | -43.6% | -17.9% |
| Sep 2001 | Oct 2001 | 2 | 17.1% | -43.3% | -56.7% |
| Feb 2002 | Sep 2005 | 184 | 76.9% | -70.8% | -66.2% |
| Feb 2010 | Feb 2010 | 1 | 3.0% | -11.0% | -76.0% |
| May 2010 | May 2011 | 53 | 37.0% | +29.7% | -70.7% |
| Jun 2011 | Feb 2012 | 37 | 24.1% | +4.3% | -77.4% |
| Mar 2012 | Apr 2012 | 4 | 6.2% | +10.6% | -77.5% |
| May 2012 | Jul 2012 | 5 | 6.5% | +39.7% | -77.7% |
| Oct 2013 | Oct 2013 | 1 | 1.9% | +65.8% | -77.5% |
| Dec 2013 | Jan 2014 | 1 | 9.1% | +63.3% | -75.8% |
| Jun 2016 | Sep 2017 | 65 | 51.3% | -29.0% | -83.5% |
| Oct 2017 | Nov 2017 | 2 | 9.8% | +35.0% | -82.0% |
| Mar 2018 | May 2018 | 8 | 11.0% | +11.5% | -83.0% |
| Nov 2018 | Mar 2019 | 18 | 15.0% | -23.4% | -83.4% |
| May 2019 | Jul 2019 | 12 | 24.8% | -47.9% | -81.7% |
| Aug 2019 | Oct 2019 | 9 | 27.2% | -50.1% | -79.8% |
| Nov 2019 | Jan 2021 | 64 | 61.4% | -39.6% | -78.3% |
| Apr 2021 | Apr 2021 | 1 | 2.0% | -12.2% | -81.3% |
| May 2021 | Jun 2021 | 4 | 2.0% | -18.3% | -81.3% |
| Nov 2021 | Jul 2022 | 35 | 36.6% | -26.2% | -80.8% |
| Aug 2022 | May 2023 | 41 | 39.3% | -31.2% | -79.4% |
| Jun 2023 | Jun 2023 | 1 | 0.3% | +6.6% | -77.5% |
| Jul 2023 | Feb 2024 | 30 | 36.8% | +17.4% | -77.2% |
| Mar 2024 | May 2024 | 8 | 18.6% | -52.4% | -75.8% |
| Jun 2024 | Jun 2024 | 1 | 2.4% | -77.0% | -76.9% |
| Oct 2024 | Ongoing | 69+ | 81.9% | Ongoing | -78.1% |
| Average | 29 | — | +-10.8% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02